EP1624758A4 - Cellules souches hematopoietiques et methodes de traitement de maladies oculaires neovasculaires utilisant ces cellules souches - Google Patents

Cellules souches hematopoietiques et methodes de traitement de maladies oculaires neovasculaires utilisant ces cellules souches

Info

Publication number
EP1624758A4
EP1624758A4 EP04760595A EP04760595A EP1624758A4 EP 1624758 A4 EP1624758 A4 EP 1624758A4 EP 04760595 A EP04760595 A EP 04760595A EP 04760595 A EP04760595 A EP 04760595A EP 1624758 A4 EP1624758 A4 EP 1624758A4
Authority
EP
European Patent Office
Prior art keywords
lin
isolated
monocytes
hscs
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP04760595A
Other languages
German (de)
English (en)
Other versions
EP1624758A2 (fr
Inventor
Martin Friedlander
Atsushi Otani
Karen Dasilva
Stacey Hanekamp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/628,783 external-priority patent/US7153501B2/en
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Priority to EP05025978A priority Critical patent/EP1754783A1/fr
Publication of EP1624758A2 publication Critical patent/EP1624758A2/fr
Publication of EP1624758A4 publication Critical patent/EP1624758A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des populations isolées de cellules souches hématopoïétiques à lignage négatif, dérivées de la moelle osseuse d'un mammifère adulte (Lin-HSC), contenant des cellules progénitrices endothéliales (EPC) capables de soigner les vaisseaux sanguins rétiniens et les réseaux neuronaux de l'oeil. De préférence, au moins 20 % environ des cellules dans les populations isolées expriment l'antigène de surface CD31. Les populations isolées sont destinées au traitement de maladies vasculaires oculaires. Dans un mode de réalisation préféré, les populations sont isolées par extraction de moelle osseuse d'un mammifère adulte ; séparation d'une pluralité de monocytes de la moelle osseuse ; marquage des monocytes à l'aide de conjugués anticorps-biotine sur un ou plusieurs antigènes de surface de lignage ; élimination des monocytes qui sont positifs pour les antigènes de surface de lignage à partir de la pluralité de monocytes, et récupération d'une population contenant les cellules progénitrices endothéliales. L'invention concerne également des populations isolées qui ont été transfectées par des gènes utiles sur le plan thérapeutiques, utilisées pour administrer des gènes à l'oeil pour une thérapie génique cellulaire. L'invention concerne également des méthodes destinées à la préparation de ces populations de cellules souches isolées, ainsi que des méthodes de traitement de maladies et de lésions oculaires.
EP04760595A 2003-05-02 2004-04-28 Cellules souches hematopoietiques et methodes de traitement de maladies oculaires neovasculaires utilisant ces cellules souches Ceased EP1624758A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05025978A EP1754783A1 (fr) 2003-05-02 2004-04-28 Cellules souches hematopoiétiques et méthodes de traitement de maladies oculaires néovasculaires utilisant ces cellules souches

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46705103P 2003-05-02 2003-05-02
US10/628,783 US7153501B2 (en) 2002-07-25 2003-07-25 Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
PCT/US2004/012989 WO2004098499A2 (fr) 2002-07-25 2004-04-28 Cellules souches hematopoietiques et methodes de traitement de maladies oculaires neovasculaires utilisant ces cellules souches

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP05025978A Division EP1754783A1 (fr) 2003-05-02 2004-04-28 Cellules souches hematopoiétiques et méthodes de traitement de maladies oculaires néovasculaires utilisant ces cellules souches

Publications (2)

Publication Number Publication Date
EP1624758A2 EP1624758A2 (fr) 2006-02-15
EP1624758A4 true EP1624758A4 (fr) 2007-03-07

Family

ID=36908146

Family Applications (2)

Application Number Title Priority Date Filing Date
EP05025978A Ceased EP1754783A1 (fr) 2003-05-02 2004-04-28 Cellules souches hematopoiétiques et méthodes de traitement de maladies oculaires néovasculaires utilisant ces cellules souches
EP04760595A Ceased EP1624758A4 (fr) 2003-05-02 2004-04-28 Cellules souches hematopoietiques et methodes de traitement de maladies oculaires neovasculaires utilisant ces cellules souches

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP05025978A Ceased EP1754783A1 (fr) 2003-05-02 2004-04-28 Cellules souches hematopoiétiques et méthodes de traitement de maladies oculaires néovasculaires utilisant ces cellules souches

Country Status (10)

Country Link
EP (2) EP1754783A1 (fr)
JP (2) JP4714682B2 (fr)
KR (3) KR101224375B1 (fr)
CN (2) CN1831119B (fr)
AU (2) AU2004237749B2 (fr)
BR (1) BRPI0409861A (fr)
CA (2) CA2524063C (fr)
MX (2) MXPA05011752A (fr)
RU (2) RU2345780C2 (fr)
ZA (2) ZA200509756B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2554662A1 (fr) * 2011-08-05 2013-02-06 M Maria Pia Cosma Procédés pour le traitement de maladies rétiniennes dégénératives
US9265813B2 (en) 2011-10-27 2016-02-23 Wellstat Ophthalmics Corporation Vectors encoding rod-derived cone viability factor
RU2495650C1 (ru) * 2012-02-29 2013-10-20 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Трехкомпонентный комплекс для клеточной терапии в офтальмологии
RU2485922C1 (ru) * 2012-03-28 2013-06-27 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Способ лечения "сухой" формы возрастной макулярной дегенерации
CN107043699B (zh) * 2017-04-25 2023-04-07 徐子雁 一种低能量激光诱导间充质干细胞血管化的试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020098521A1 (en) * 2000-10-18 2002-07-25 Dominique Bonnet Method and marker for the isolation of human multipotent hematopoietic stem cells
WO2004010959A2 (fr) * 2002-07-25 2004-02-05 The Scripps Research Institute Cellules souches hematopoietiques et methodes de traitement de maladies oculaires neovasculaires faisant intervenir ces cellules souches

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020098521A1 (en) * 2000-10-18 2002-07-25 Dominique Bonnet Method and marker for the isolation of human multipotent hematopoietic stem cells
WO2004010959A2 (fr) * 2002-07-25 2004-02-05 The Scripps Research Institute Cellules souches hematopoietiques et methodes de traitement de maladies oculaires neovasculaires faisant intervenir ces cellules souches

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GALLACHER LISA ET AL: "Isolation and characterization of human CD34-Lin- and CD34+Lin- hematopoietic stem cells using cell surface markers AC133 and CD7", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 95, no. 9, 1 May 2000 (2000-05-01), pages 2813 - 2820, XP002303837, ISSN: 0006-4971 *
INTERNET CITATION: "StemSepTM Human Primitive Progenitor Enrichment Kit", Retrieved from the Internet <URL:http://www.stemcell.com/product_catalog/product_catalog_index.aspx?print=1&id=519&type=catalog_item> [retrieved on 20100427] *
OTANI ATSUSHI ET AL: "Rescue of retinal degeneration by intravitreally injected adult bone marrow-derived lineage-negative hematopoietic stem cells.", THE JOURNAL OF CLINICAL INVESTIGATION. SEP 2004, vol. 114, no. 6, September 2004 (2004-09-01), pages 765 - 774, XP002413476, ISSN: 0021-9738 *
WATANABE M ET AL: "Intravitreal injections of neurotrophic factors and forskolin enhance survival and axonal regeneration of axotomized beta ganglion cells in cat retina.", NEUROSCIENCE. 2003, vol. 116, no. 3, 2003, pages 733 - 742, XP002413475, ISSN: 0306-4522 *
YIN A H ET AL: "AC133, a novel marker for human hematopoietic stem and progenitor cells.", BLOOD. 15 DEC 1997, vol. 90, no. 12, 15 December 1997 (1997-12-15), pages 5002 - 5012, XP002264586, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
ZA200509756B (en) 2006-10-25
EP1754783A1 (fr) 2007-02-21
KR20060008968A (ko) 2006-01-27
CA2524063A1 (fr) 2004-11-18
AU2005239702B2 (en) 2010-03-04
JP4714682B2 (ja) 2011-06-29
KR20060056420A (ko) 2006-05-24
CA2526670C (fr) 2011-06-14
CA2526670A1 (fr) 2004-11-18
KR20120034251A (ko) 2012-04-10
BRPI0409861A (pt) 2006-05-16
EP1624758A2 (fr) 2006-02-15
KR101169261B1 (ko) 2012-08-03
JP2006525806A (ja) 2006-11-16
KR101224375B1 (ko) 2013-01-21
CA2524063C (fr) 2015-02-17
RU2345780C2 (ru) 2009-02-10
AU2004237749A1 (en) 2004-11-18
AU2005239702A1 (en) 2005-12-22
CN1816281A (zh) 2006-08-09
CN1831119B (zh) 2010-05-26
MXPA05011750A (es) 2006-06-06
CN100439493C (zh) 2008-12-03
RU2006103574A (ru) 2007-08-20
MXPA05011752A (es) 2006-06-06
JP4714580B2 (ja) 2011-06-29
RU2389497C2 (ru) 2010-05-20
AU2004237749B2 (en) 2011-09-15
RU2005137569A (ru) 2006-06-10
CN1831119A (zh) 2006-09-13
ZA200509752B (en) 2006-11-29
JP2006166918A (ja) 2006-06-29

Similar Documents

Publication Publication Date Title
WO2004098499A3 (fr) Cellules souches hematopoietiques et methodes de traitement de maladies oculaires neovasculaires utilisant ces cellules souches
JP2014507389A (ja) 羊膜由来接着細胞を使用する脊髄損傷及び外傷性脳損傷の治療
EP2171042B1 (fr) Immunomodulation de cellule t par des préparations de cellules de placenta
JP2014507390A (ja) 胎盤幹細胞を用いる脊髄損傷及び外傷性脳損傷の治療
EP1915440A2 (fr) Compositions cellulaires enrichies destines a la combinaison de diverses populations cellulaires a base de cellules souches et de cellules progenitrices, leurs methodes d&#39;utilisation, et methodes de mise en banque privee
AU2007247725B2 (en) Immune privileged and modulatory progenitor cells
RU2007135220A (ru) Способ лечения ретинопатии при недоношенности и родственных ретинопатических заболеваний
CA2862661A1 (fr) Methodes et compositions permettant l&#39;obtention, a des fins cliniques, d&#39;une cellule allogene et ses utilisations therapeutiques
WO2008063564A3 (fr) Populations cellulaires de type myéloïde isolées et procédés de traitement avec celles-ci
Sundin et al. HSCT recipients have specific tolerance to MSC but not to the MSC donor
WO2020146874A1 (fr) Cellules fibroblastes régénératrices
CA3100247A1 (fr) Cellules immunitaires resistant aux medicaments et leurs procedes d&#39;utilisation
Atmaca-Sonmez et al. Systemically transferred hematopoietic stem cells home to the subretinal space and express RPE-65 in a mouse model of retinal pigment epithelium damage
WO2006031467A3 (fr) Cellules souches hematopoietiques de lignees negatives isolees et methodes de traitement associees
WO2006104609A3 (fr) Populations isolees de cellules de moelle osseuse de type myeloide et methodes de traitement correspondantes
EP1624758A4 (fr) Cellules souches hematopoietiques et methodes de traitement de maladies oculaires neovasculaires utilisant ces cellules souches
JP2006166918A5 (fr)
Kath et al. CAR NK-92 cell–mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products
EP3075845B1 (fr) Nouveau marqueur de surface de cellules souches mésenchymateuses
Engler et al. Comparison of non-viral methods to genetically modify and enrich populations of primary human corneal endothelial cells
US20230414720A1 (en) Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes
Nan et al. In Vitro Study of Adipose-Derived Mesenchymal Stem Cells Transduced with Lentiviral Vector Carrying the Brain-Derived Neurotrophic Factor Gene
Santa Cruz-Pavlovich et al. Beyond Vision: An Overview of Regenerative Medicine and Its Current Applications in Ophthalmological Care
US20190358268A1 (en) Methods of Treating HIV Infection with Allogeneic CCR5 Null Umbilical Cord Blood Cells
CN117660538A (zh) 一种具有增强免疫抑制能力和迁移能力的间充质干细胞及其在gvhd上的应用

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051125

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/06 20060101AFI20070124BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070205

17Q First examination report despatched

Effective date: 20070702

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20101115